623 related articles for article (PubMed ID: 26037043)
21. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
[TBL] [Abstract][Full Text] [Related]
22. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
23. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
[TBL] [Abstract][Full Text] [Related]
24. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
25. NLX-112, a highly selective 5-HT
Newman-Tancredi A; Depoortère R; Carilla-Durand E; Tarayre JP; Kleven M; Koek W; Bardin L; Varney MA
Pharmacol Biochem Behav; 2018 Feb; 165():56-62. PubMed ID: 29126856
[TBL] [Abstract][Full Text] [Related]
26. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
27. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
28. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
29. The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat.
Jastrzębska-Więsek M; Wesołowska A; Kołaczkowski M; Varney MA; Newman-Tancredi A; Depoortere R
Behav Pharmacol; 2022 Aug; 33(5):333-341. PubMed ID: 35695543
[TBL] [Abstract][Full Text] [Related]
30. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
[TBL] [Abstract][Full Text] [Related]
31. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Dupre KB; Eskow KL; Barnum CJ; Bishop C
Neuropharmacology; 2008 Dec; 55(8):1321-8. PubMed ID: 18824001
[TBL] [Abstract][Full Text] [Related]
32. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats.
Smith S; Sergio J; Coyle M; Elder K; Centner A; Cohen S; Terry M; Lipari N; Glinski J; Wheelis E; Budrow C; Bishop C
Psychopharmacology (Berl); 2022 Jul; 239(7):2119-2132. PubMed ID: 35275226
[TBL] [Abstract][Full Text] [Related]
33. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM
Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Thomsen M; Stoica A; Christensen KV; Fryland T; Mikkelsen JD; Hansen JB
Exp Neurol; 2022 Dec; 358():114209. PubMed ID: 35988699
[TBL] [Abstract][Full Text] [Related]
35. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Dupre KB; Eskow KL; Negron G; Bishop C
Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
[TBL] [Abstract][Full Text] [Related]
36. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
37. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Tani Y; Ogata A; Koyama M; Inoue T
Eur J Pharmacol; 2010 Dec; 649(1-3):218-23. PubMed ID: 20858480
[TBL] [Abstract][Full Text] [Related]
38. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
39. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
40. Activity of Serotonin 5-HT
Jastrzębska-Więsek M; Partyka A; Rychtyk J; Śniecikowska J; Kołaczkowski M; Wesołowska A; Varney MA; Newman-Tancredi A
ACS Chem Neurosci; 2018 May; 9(5):1040-1050. PubMed ID: 29266914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]